Delamanid and pretomanid

Research output: Chapter in Book/Report/Conference proceedingChapter


Delamanid (Deltyba, formerly OPC-67683) and pretomanid (formerly PA-824) are two bicyclic 4-nitroimidazoles in development for treatment of tuberculosis. Delamanid was conditionally approved in Europe in 2013 and approved in Japan in 2014 for the treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with an appropriate background regimen; pretomanid remains investigationalonly as of this writing but is being evaluated as part of combination regimens for treatment of both drug-susceptible and MDR-TB.

Original languageEnglish (US)
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Number of pages9
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • General Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Delamanid and pretomanid'. Together they form a unique fingerprint.

Cite this